Aphria Medical Marijuana Pitch Deck: 17-Slide Breakdown

The Aphria 2015 investor presentation is a study in operational transparency for a capital-intensive industry. Rather than focusing on the cultural zeitgeist of cannabis, the deck treats medical marijuana as a high-stakes agricultural and pharmaceutical play. With a management team boasting over 75 combined years of experience in pharma and agri-business (Slide 3), the narrative centers on production efficiency and capacity expansion. The deck provides specific inventory projections, such as a June 2015 target of ~550 kg (Slide 7), and a clear $7.5 million capital expenditure roadmap to quadr…

Key takeaways

• The management team is positioned as a primary asset, citing over 75 years of combined experience in pharmaceutical and agricultural sectors on Slide 3.
• Aphria identifies as a TSXV-listed entity (TSXV:APH) as of the February 2015 presentation date on Slide 1.
• The company maps its competitive landscape across Canada, identifying 14 other licensed producers including Tilray and Tweed on Slide 5.
• Production scaling is quantified with a goal of reaching a run rate of 110-120 kg per month by June 2015, as shown on Slide 7.
• The growth strategy is segmented into three pillars: Patient Acquisition, Increase Harvest Yields, and Facility Expansion on Slide 9.
• Technical yield improvements are categorized into four operational areas: Shaping, Sizing, Spacing, and Selection on Slide 11.
• A specific $7.5 million CAPEX plan is detailed to quadruple production capacity to 100,000 sq. ft. on Slide 13.
• The deck anticipates future regulatory shifts, specifically mentioning potential legalization of recreational use and edibles/oil on Slide 15.

Frequently asked questions

What is Aphria's primary competitive advantage according to the deck?

Aphria emphasizes its leadership team's deep roots in traditional industry. Slide 3 highlights CEO Vic Neufeld’s 20+ years in pharma and Co-Founders Cole Cacciavillani and John Cervini’s extensive agricultural backgrounds (35+ and 20+ years respectively). This suggests a focus on professionalized, large-scale operations rather than a 'startup' approach to cannabis.

How does the company plan to improve its production efficiency?

Slide 11 outlines a four-step process to increase harvest yields: Shaping, Sizing, Spacing, and Selection. While the slide is high-level, it signals to investors that the company is focused on the granular, technical aspects of agricultural optimization to drive margins.

What are the specific financial requirements for their expansion?

Slide 13 details a $7.5 million expansion cost to reach 100,000 sq. ft. of production space. It provides a quarterly CAPEX schedule starting at $0.8M in Q3 2015 and peaking at $3.75M in Q2 2016, showing a clear roadmap for capital deployment.

Does the deck address the recreational marijuana market?

Yes, but as a long-term opportunity. Slide 15 categorizes 'Legalization of recreational use' and 'Edibles & oil' under mid-to-long-term opportunities driven by changes in the regulatory environment, keeping the immediate focus on the existing medical framework.

What was Aphria's cash position at the start of 2015?

According to Slide 13, Aphria reported a cash position of approximately $10.0 million as of January 1, 2015. This figure was used to anchor their ability to fund the $7.5 million expansion project described in the same slide.

Aphria Medical Marijuana pitch deck: the facts

Company

Aphria Medical Marijuana

Slides

17

Sector

Cannabis

Aphria Medical Marijuana pitch deck PDF

The full Aphria Medical Marijuana deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Aphria Inc. (Aphria Medical Marijuana) pitch deck was used for

This is Aphria Inc.’s **February 2015 “Aphria Medical Marijuana Investor Presentation”**, a 17‑slide investor deck aimed at public‑market and institutional investors following its early listing on the TSX Venture Exchange. The presentation frames Aphria as a Health Canada–licensed, greenhouse‑based medical marijuana producer in Leamington, Ontario, emphasizing its evolution from a small licensed facility into a scaled, low‑cost agricultural cannabis platform. The deck appears to precede or accompany a period of equity and unit financings and greenhouse expansion transactions in 2015–2016, where Aphria raised capital and acquired additional greenhouse acreage in Leamington. It positions the company as a growth‑stage, revenue‑generating licensed producer raising capital to expand production capacity, inventory and patient acquisition rather than a pre‑revenue startup.

Business model: Licensed producer that **produces, supplies and sells medical cannabis** to the Canadian market under federal regulations, operating as a greenhouse-based, low-cost agricultural producer.

Headquarters

Leamington, Ontario, Canada

Industry

Medical cannabis / regulated cannabis production.

Round: Growth‑stage public company financing via bought‑deal equity offerings and debt, rather than a private venture round.

Year: 2015 (bought‑deal unit financing closed December 11, 2015), followed by additional major raises in 2017.

Raised: Net proceeds of approximately **$10,485,264** from a bought‑deal unit financing announced as closed on December 11, 2015; Aphria later raised **$100 million** (including a $75 million bought‑deal equity financing and $25 million term loan) announced in April 2017.

Lead investor: Clarus Securities Inc. acted as underwriter and lead on at least one bought‑deal equity financing for Aphria (e.g., the $75 million equity component of the $100 million raise announced in April 2017).

Use of funds as presented: Proceeds were used primarily to fund **expansion of production capacity, acquisition and development of additional greenhouse facilities in Leamington, Ontario, inventory build‑up, and other strategic opportunities** in the medical cannabis market.

What happened after the Aphria Inc. (Aphria Medical Marijuana) deck

Following its 2015 medical marijuana investor deck, Aphria progressed from a single 30,000 sq ft licensed greenhouse producing 700 kg annually to a significantly larger, well‑financed medical cannabis producer. It executed bought‑deal financings in 2015, 2017 and 2018, secured a $100 million raise combining equity and debt in 2017, and acquired additional greenhouse acreage in Leamington through a

• Health Canada granted Aphria a license to produce and sell medical cannabis in 2014, establishing its status as a regula
• By December 11, 2015, Aphria closed a **bought‑deal unit financing**, issuing 8,846,370 units (one share plus half‑warra
• Subsequent to this period, Aphria entered into a purchase agreement to acquire **9 acres of greenhouses on 36 acres of p
• In April 2017, Aphria announced it had secured a **$100 million raise**, combining a $75 million bought‑deal equity fina
• By November 2017, Aphria completed a **C$92 million bought‑deal offering**, selling 12,689,675 common shares at $7.25 pe
• Later reports show Aphria scaling to very large greenhouse operations, including facilities such as Aphria Diamond, whic

What the Aphria Inc. (Aphria Medical Marijuana) deck got right

• Deeply experienced, sector‑relevant leadership with significant insider ownership. The deck’s **“Highly Experienced Management Team”** slide foregrounds Vic Neufeld’s 20+ years in pharma and tenure as CEO of Jamieson Laboratories, alongside co‑founders with decades of greenhouse and agri‑business experience and substantial beneficial ownership, giving investors confidence in both regulatory navigation and agricultural execution.
• Concrete, licensed operating base in Leamington greenhouse facilities. Aphria’s positioning as a **Health Canada–licensed greenhouse producer** with an existing 30,000 sq ft facility and a 700 kg annual production license provides tangible operational proof points, differentiating it from more speculative cannabis ventures and aligning with the deck’s emphasis on being a scaled agricultural powerhouse.
• Clear near‑term production run‑rate and inventory scaling plan. The “Growing Production, Inventory and Sales” slide gives **specific production run‑rate targets** (110–120 kg per month by June 2015, two harvests per month) and visualizes inventory and sales ramp, offering investors a clear near‑term growth trajectory grounded in physical output rather than purely in top‑down market sizing.
• Compelling low‑cost producer narrative anchored in greenhouse operations. The deck consistently emphasizes Aphria as **one of Canada’s lowest‑cost producers**, leveraging greenhouse expertise and sunlight to achieve cost advantage, which is supported by later descriptions of Aphria in financings and press releases as a low‑cost medical cannabis producer.
• Strategic framing as a scalable agricultural cannabis platform. By framing the company as transitioning from a licensed producer to a **scaled agricultural platform**, the deck speaks to scalability and repeatability of operations in a way that resonates with institutional investors more familiar with agriculture and manufacturing businesses than with early‑stage biotech.
• Professional capital‑markets presentation with clear forward‑looking disclosure. The inclusion of a **Forward‑Looking Statements** slide early in the deck reflects a level of capital‑markets sophistication and regulatory awareness appropriate for a TSX Venture–listed issuer, helping institutional investors contextualize projections within securities‑law‑compliant disclosure.

What could have been stronger

• Risks referenced but not deeply quantified or scenario‑tested. The deck’s “Forward‑Looking Statements” slide explicitly warns that forward‑looking statements involve numerous known and unknown risks, but the presentation itself provides **limited quantitative detail on specific risk scenarios** (e.g., regulatory changes, pricing compression, or oversupply) and how Aphria would mitigate them. This can leave investors without a clear view of downside scenarios relative to the bullish growth projections included elsewhere in the deck.
• Limited governance and related‑party transparency in the deck. Although the management slide foregrounds extensive pharma and greenhouse experience and significant insider ownership, the deck **does not present a detailed governance, related‑party transaction or conflict‑of‑interest discussion**, even as later filings show non‑arm’s‑length greenhouse acquisitions from insider vendors. For an institutional investor, the lack of upfront detail on governance practices in the deck itself is a notable omission.
• Production growth shown without equally detailed demand and pricing data. The “Growing Production, Inventory and Sales” slide quantifies production run‑rate targets (110–120 kg per month, two harvests per month) and inventory builds, but **does not show parallel metrics on patient count, churn, or pricing assumptions** that connect production growth to sustainable demand. Without more granular demand and pricing data, investors must infer how Aphria avoids overproduction or inventory write‑downs.
• Low‑cost claim not backed by visible per‑unit economics in the slides. The deck’s emphasis on being one of the lowest‑cost producers and on greenhouse efficiency is strong, but **unit cost data, margin breakdowns or sensitivity analyses are not fully visible in the slide excerpts**. For a capital‑intensive agricultural business, investors may see the absence of explicit per‑gram cost curves and margin trajectories as a gap in the story.
• Limited emphasis on differentiated product or IP strategy. While the deck references Aphria’s licensing and regulatory compliance, there is **little detail on product differentiation (strains, formulations, clinical data) or intellectual property**, leaving the impression that the core edge is cost and scale rather than product innovation. For some investors, this could raise questions about long‑term defensibility beyond being a cheap, large greenhouse grower.

How an investor would read this deck

What draws attention

• Experienced management team with deep pharma and greenhouse operating backgrounds (Vic Neufeld, Cole Cacciavillani, John Cervini) and meaningful insider ownership, which supports the credibility of scaling a greenhouse‑based medical cannabis producer.
• Regulated status as a **Health Canada Licensed Producer** under MMPR/ACMPR, with an existing 30,000 sq ft greenhouse licensed to produce and sell 700 kg annually, gives Aphria a tangible operating base rather than a purely speculative cannabis concept.
• Clear focus on **low‑cost greenhouse production in Leamington, Ontario**, leveraging decades of agri‑business experience, which directly addresses investor concerns around sustainable cost advantage as the market matures.
• Demonstrated access to capital markets via bought‑deal financings and equity offerings in 2015 and later years, indicating institutional interest and the ability to fund expansion of production capacity and greenhouse footprint.
• Visibility into near‑term production scaling, with the deck showing a monthly production run rate target of 110–120 kg by June 2015, aligned to patient acquisition growth and inventory build‑up.

Risks that stand out

• Regulatory risk: Aphria’s ability to grow, store, and sell medical marijuana depends on maintaining its Health Canada license and on the stability of federal regulations; changes in licensing regimes or compliance issues could materially affect operations.
• Financing and dilution risk: The company relies on equity financings and bought‑deal offerings to fund expansion, which can dilute existing shareholders and create expectations for continual capital raising if internal cash generation lags growth plans.
• Agricultural and operational risk: As a greenhouse‑based producer, Aphria faces crop, pest, and yield risks, as well as execution risk in ramping production from hundreds to thousands of kilograms annually while maintaining quality and compliance.
• Market and pricing risk: The deck presumes significant growth in registered medical cannabis patients and associated revenues, but over‑estimation of demand or increased competition from other low‑cost producers could compress prices and margins, leading to inventory risks.
• Governance and related‑party risk: Non‑arm’s‑length transactions for greenhouse assets from insiders underscore the importance of strong governance; without robust oversight, investors face potential conflicts of interest or value transfer away from minority shareholders.

Questions this deck invites

• How did Aphria’s actual 2015–2017 production volumes, patient counts, and revenue compare to the run‑rate and market‑growth projections presented in the February 2015 deck, and where did forecasts materially diverge?
• What specific **unit cost per gram**, gross margin, and return‑on‑capital metrics did Aphria achieve from its Leamington greenhouse operations, and how did these compare to competing licensed producers over the subsequent years?
• How were **related‑party greenhouse acquisitions** (such as the $6.5 million purchase of 9 acres of greenhouses from an insider vendor) structured, approved, and disclosed, and what safeguards were in place to protect minority shareholders?
• To what extent did Aphria diversify beyond basic dried flower products into oils, derivatives, or international markets, and how does that evolution relate back to the strategic focus communicated in this 2015 medical marijuana deck?
• What regulatory, pricing, or competitive pressures emerged after 2015 that were not fully anticipated in this deck’s forward‑looking statements, and how did Aphria adapt its strategy and capital structure in response?

What founders can take from the Aphria Inc. (Aphria Medical Marijuana) deck

• Aphria’s 2015 deck shows how a cannabis company can **anchor its story in tangible agricultural assets and operating licenses**, rather than purely in market hype, by highlighting an existing licensed greenhouse facility and quantified production run‑rates.
• Emphasizing a **management team with sector‑relevant experience** (pharma and greenhouse operations) and significant insider ownership can be a powerful way to convince investors that execution risk is manageable and that leadership is aligned with shareholder value.
• Clearly presenting **forward‑looking statements and risk disclaimers** at the front of an investor deck sets expectations about uncertainty while still allowing the company to share aggressive growth projections under regulatory constraints.
• Aphria’s use of the deck in a period leading up to and surrounding bought‑deal financings illustrates how **public‑market cannabis issuers leverage investor presentations to support capital raising** for facility expansion and inventory build‑up.
• Framing the business primarily around **cost advantage and scalable greenhouse infrastructure** can differentiate a producer in a commoditizing market, but it also highlights the importance of later adding detail on unit economics, demand assumptions, and governance to sustain investor confidence.
• The subsequent history of Aphria’s financings and expansion activity indicates that investor decks should be treated as **snapshots of intent**, and that investors must later compare actual performance and transactions against what was promised to assess credibility and execution quality.

Aphria Inc. (Aphria Medical Marijuana) pitch deck: common questions

What does Aphria Medical Marijuana do, according to the 2015 investor deck?

Aphria Inc. is a **licensed producer of medical cannabis** in Canada that operates greenhouse facilities in Leamington, Ontario, supplying regulated medical marijuana products to patients under federal cannabis regulations. The 2015 investor deck presents Aphria as a low‑cost, agriculture‑driven producer transitioning from a single licensed facility toward larger scale production.

What production capacity and facilities does Aphria highlight in this presentation?

The 2015 deck shows Aphria as a licensed producer with a **30,000 square foot greenhouse facility in Leamington, Ontario**, at that time licensed to produce and sell **700 kg of medical marijuana annually**. The deck’s later slides (and supporting research) indicate plans to expand production capacity and greenhouse footprint, including acquiring another 9 acres of greenhouses on 36 acres of property for $6.5 million in a non‑arm’s‑length transaction announced in 2016.

What fundraise or financing period is associated with this 2015 Aphria investor deck?

While the Slideshare deck itself does not explicitly label a specific round size on the public page, Aphria’s subsequent filings and MD&A show that in **December 2015 the company closed a bought‑deal unit financing**, issuing **8,846,370 units**, each with one share and a half‑warrant, for **net proceeds of approximately $10.49 million**. The 2015 investor deck fits into this financing and expansion period, designed to explain its growth plan and support capital raising for greenhouse expansion and inventory build‑up.

Is this deck about recreational cannabis or medical cannabis?

The 2015 deck emphasizes **medical use only**, with references to Health Canada licensing and regulated patient acquisition. Aphria’s business at the time was focused on medical marijuana under the Marihuana for Medical Purposes Regulations (MMPR), and it describes itself as a Health Canada Licensed Producer of medical cannabis products—not a recreational brand.

Who are the key executives featured in the 2015 Aphria Medical Marijuana deck?

In the slides, Aphria highlights a **highly experienced management team**: Vic Neufeld (CEO) with 20+ years in pharma and former CEO of Jamieson Laboratories; and co‑founders Cole Cacciavillani and John Cervini with decades of greenhouse and agri‑business experience. The deck also notes their significant beneficial share ownership (e.g., 18.9% and 21.9% for the co‑founders), intended to signal strong alignment with shareholders.

Sources

Funding and outcome facts on this page were researched on 2026-08-21 from the pages below.

• 2015 Aphria Medical Marijuana Investor Presentation
• Microsoft Word - APH-2014-12-19-ClarusRR
• [PDF] MANAGEMENT'S DISCUSSION & ANALYSIS COMPANY OVERVIEW
• Jonathan Leong | LinkedIn
• aphria inc.
• Aphria Inc. - Wikipedia
• Aphria Announces Closing of Bought Deal Financing
• POWERED BY SUNLIGHT

Aphria Medical Marijuana pitch deck slides

What each slide of the Aphria Medical Marijuana pitch deck says

Slide 2

Forward-Looking Statements Certain information in this presentation constitutes forward-looking statements under applicable securities law. Any statements that are contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may', "should", "anticipate", "expect", "intend" and similar expressions. Forward-looking statements in this presentation include, but are not limited to, statements with respect to Aphria's intended business focus. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with genera…

Slide 3

HIGHLY EXPERIENCED MANAGEMENT TEAM Vic Neufeld Chief Executive Officer 20+Years in pharma CEO of Jamieson Laboratories 1993-2014 Demonstrated vision, growth & performance Beneficial ownership: 1.3% of APH shares *\phria Cole Cacciavillani Co-Founder & Chief Operating Officer 3 5+Years in agri-business Greenhouse industry pioneer and veteran First-hand knowledge of Aphria's greenhouses Beneficial ownership: 18.9% of APH shares John Cervini Co-Founder & Chief Agronomist Officer 20+Years in agri-business Fourth generation greenhouse grower Proven growth and expansion track record Beneficial ownership: 21.9% of APH shares

Slide 4

Aan —.. INVESTMENT HIGHLIGHTS Ea BE TT aay — TT Te= Tae + Established operations & experienced management to. costs i Re wld ia model High growth industry offers significant opportunity. License to sell MMJ provides critical barrier to entry Well cafitaiized Rk Attractive cash flow potential

Slide 5

EE CANADIAN LICENSED MEDICAL MARIJUANA PRODUCERS Peace Naturals Project OrganiGram Lal In the Zone WMMC o o ’ / Thunderbird * . 3 [ i fli Biomedical 0) 0) | I Tilray \ o) \ Ss { Broken Coast Cannabis ) ~ a gS Tweed \ * sane] Cannimed SE = Bedrocan G phria dota Aphriad® > preeteet : _____________________________ aaa aa—

Slide 6

HIGH GROWTH CANADIAN MMJ INDUSTRY $1.4 Billion «Canadian medical marijuana industry (MM) industry expected to grow exponentially over next 10 years $150 Million — Patient users anticipated to increase from 40K to 400K 400,000 — Sales projected to grow from po 00 MMJ FLSOM tis 1 45) Patient Patient + MMI clinics opening up across Users Canada Users + Increasing awareness of MMJ 2014 \ i By 2024 “\phria ri o_O

Slide 7

GROWING PRODUCTION, INVENTORY AND SALES June 2015 inventory: Dec Jan Mar Apr May Nov mmm KGs produced @ Estimate Sales (KG) Ending Inventory Aphria's monthly production is estimated to reach a run rate of 110-120 kg (2 harvests per month) by June 2015 as sales ramp commensurate with patient acquisition growth. (*\phria

Slide text above is read directly from the Aphria Medical Marijuana deck PDF embedded on this page.

Related fundraising guides (24)

• Comprehensive Pitch Deck Teardown: A Masterclass in Founder-Market Fit and Category Creation
• Bringg Pitch Deck Teardown: A Masterclass in Enterprise SaaS Traction and Scale
• Arkestro Pitch Deck Teardown: A Masterclass in Social Proof and Domain Authority
• Agave Games Pitch Deck Teardown: A $7M Seed Round Built on Mobile Gaming Pedigree
• Staffjoy Pitch Deck Teardown: A Masterclass in Algorithmic Workforce Automation
• Sunnyside Pitch Deck Teardown: A Masterclass in Market Expansion via Habit Modification
• Hone Pitch Deck Teardown: Defining the 'Missing Middle' of Corporate Learning
• Green Li-ion Pitch Deck Teardown: A Masterclass in Supply Chain Disruption for Battery Recycling
• EnergyX Pitch Deck Teardown: A Masterclass in Industrial Validation and Scientific Pedigree
• Cowboy Pitch Deck Teardown: A Masterclass in High-End Lifestyle Branding and Urban Mobility
• Calico Pitch Deck Teardown: A 6-Slide Masterclass in Supply Chain Simplification
• Auki Labs Pitch Deck Teardown: A $13M Bet on Replacing GPS for the Spatial Metaverse
• Friday Finance Pitch Deck Teardown: A $20M Series A Built on Aggregation and Social Proof
• Connected Analytics Pitch Deck Teardown: Solving the Cash-Loyalty Gap in Africa
• Vespa.ai Pitch Deck Teardown: A Corporate Spin-Out Strategy for High-Scale Vector Search
• HTEC Group Pitch Deck Teardown: Scaling Global Engineering Services via M&A and Talent Density
• Handly Pitch Deck Teardown: A B2B2C Play for the €5 Trillion Craft Services Market
• EVERY Pitch Deck Teardown: A $175M Masterclass in Precision Fermentation Storytelling
• Dalan Animal Health Pitch Deck Teardown: A $3.5M Seed for the First Honeybee Vaccine
• Chattermill Pitch Deck Teardown: A Masterclass in Enterprise Social Proof and Expansion Strategy
• Beam Dental Pitch Deck Teardown: A Masterclass in Structural Cost Advantage
• Alphin Pitch Deck Teardown: A $6M Series A Masterclass in Local SMB Digitization
• Nest Health Pitch Deck Teardown: A $15M Seed Strategy for Value-Based Family Care
• Trash Warrior Pitch Deck Teardown: Disrupting the $56B Commercial Waste Collection Market

Browse companies alphabetically (1)

• Pitch decks from companies starting with A

More pitch deck teardowns (16)

• AnyRoad Pitch Deck Breakdown: Defining the Experience Relationship Management Category
• APDealFlow Pitch Deck Teardown: A B2B Intermediary Network for APAC Private Equity
• Asia Pacific DealFlow Pitch Deck Teardown: A Pre-JOBS Act Deal Management Portal
• Aphea.Bio Pitch Deck Breakdown: A Masterclass in R&D Pipeline Visualization
• Aphea.Bio Pitch Deck Teardown: A Masterclass in Visualizing Complex R&D Pipelines
• Aphelion Orbitals Pitch Deck Teardown: Targeting the Nanolauch Market with $750k Launches
• Apheris Pitch Deck Breakdown: Solving the Data Silo Dilemma for Enterprise AI
• Apheros Pitch Deck Teardown: A Masterclass in High-Performance Hardware Material Science
• Apifier Pitch Deck Teardown: A $250k Seed Ask Built on Developer-First Growth
• api.video Pitch Deck Teardown: A Developer-First Approach to $12M Series A
• One Mobility Pitch Deck Teardown: Scaling Kids' Bike Subscriptions via Asset-Heavy Logistics
• Apollo Medical Holdings Pitch Deck Teardown: Scaling Integrated Care in the Medicare Market
• Apollo Pitch Deck Breakdown: Scaling the Data Graph Layer with a $130M Series D
• Appartmate Pitch Deck Teardown: A Visual-First Approach to Social Renting
• AppBind Pitch Deck Breakdown: Unlocking SaaS Reseller Channels
• APPbyYOU Pitch Deck Teardown: A White-Label Approach to Enterprise Messaging

Recently published pitch deck teardowns (12)

• Liberare Pitch Deck Teardown: A $1M Pre-Seed Strategy for Adaptive Fashion
• Liminal Pitch Deck Teardown: Quantifying the ROI of Ultrasound Battery Inspection
• Lighthouse Labs Pitch Deck Teardown: Navigating the Fragmentation of the Metaverse
• Lindus Health Pitch Deck Teardown: A Product-First Approach to Clinical Trials
• LiquidStack Pitch Deck Teardown: Riding the Generative AI Hardware Inflection Point
• Lirvana Labs Pitch Deck Teardown: A $5.3M Seed Round Built on Social Impact and Pedigree
• Little Journey Pitch Deck Teardown: Quantifying the Financial Cost of Pediatric Patient Anxiety
• LogRock Pitch Deck Teardown: A $3.5M Seed Masterclass in Niche Compliance Automation
• LTV.ai Pitch Deck Teardown: A $5.2M Series A Case Study in AI-Native Marketing
• Lumiform Pitch Deck Teardown: A Product-First Masterclass in Workflow Automation
• Lunio Pitch Deck Teardown: A $15M Series A Masterclass in Cybersecurity Pedigree
• LucidLink Pitch Deck Teardown: Solving the Latency Gap in Remote Creative Collaboration

Fundraising library · Pitch deck examples · Investor directory · Founder database